Data protection Impressum

Life sciences

Bernese start-up ATANIS Biotech has won Phase 2 of the FARE Innovation Award Diagnostic Challenge, securing USD 2 million to advance its FAST-PASE allergy test.

ATANIS Biotech secures USD 2 million for its FAST-PASE allergy test

3 March 2025

Vaud-based biopharma Oculis has successfully completed an oversubscribed USD 100 million offering, further strengthening its pipeline of innovative ophthalmic and neuro-ophthalmic treatments.

Oculis secures USD 100 million to advance its neuroprotective treatment pipeline

17 February 2025

The University Hospitals of Geneva (HUG), the Department of Health and Mobilities (DSM) of the Canton of Geneva, and the Wyss Center are joining forces to establish Switzerland’s first artificial intelligence health hub at Campus Biotech, set to open in the second half of 2025.

An artificial intelligence health hub is set to open at Campus Biotech

17 February 2025

The University Hospitals of Geneva (HUG) have introduced Switzerland’s first AI-driven medical chatbot, “confIAnce”, providing reliable, verified general medical information. This innovation represents a major step in integrating artificial intelligence into Swiss healthcare.

HUG pioneers AI-powered healthcare with Switzerland’s first medical chatbot

10 February 2025

Biotech company CELLnTEC is playing a key role in the NEOLIVER project, a European-Swiss initiative developing the world’s first autologous bioprinted liver for clinical use. The project, co-funded by the EU and the Swiss government, aims to address the global organ donor shortage through innovative bioprinting technologies.

Bern-based CELLnTEC joins NEOLIVER project to develop bioprinted liver constructs

10 February 2025

The Swiss Institute of Bioinformatics has inaugurated the Centre for Pathogen Bioinformatics in Bern, a state-of-the-art facility dedicated to strengthening genomic surveillance of infectious diseases.

The Centre for Pathogen Bioinformatics was inaugurated in Bern

4 February 2025

The Lausanne University Hospital (CHUV) has secured market authorization from Swissmedic to produce a fecal microbiota transplant (FMT) medication, making it the first accredited center in Switzerland to manufacture this treatment under strict pharmaceutical standards. This breakthrough provides an effective solution for patients suffering from recurrent Clostridioides difficile infections, a debilitating condition characterized by repeated digestive blowouts and severe discomfort.

CHUV becomes first Swiss hospital to produce gut-balancing medication

29 January 2025

The Human Lean Diagnostics (HLD) innovation cluster in Neuchâtel is preparing to welcome its first tenants in June 2025. Developed in collaboration with Microcity, the cluster is dedicated to accelerating medical diagnostics innovation by providing state-of-the-art infrastructure, fostering collaboration between industry and academia, and strengthening Switzerland’s position in health technology.

Neuchâtel’s Human Lean Diagnostics cluster is set to welcome its first tenants

29 January 2025

TheraMe!, a Lausanne-based medtech, is transforming cancer treatment by partnering with CSEM to develop an automated, microfluidic-based instrument. This breakthrough technology enables personalized drug screening on live tumor samples, providing cancer patients with tailored therapy recommendations before treatment begins.

CSEM and TheraMe! transform cancer therapy with personalized drug screening technology

28 January 2025

EPFL Innovation Park biotech company AB2 Bio has signed an option and licensing agreement with Japan-based Nippon Shinyaku to advance Tadekinig alfa, a novel treatment for Primary Monogenic IL-18 driven Hyperinflammatory Syndrome. The deal includes up to USD 36 million in early payments and milestone-based funding of up to USD 650 million.

AB2 Bio secures USD 650 million partnership with Nippon Shinyaku for rare disease therapy

27 January 2025

1 … 4 5 6 7 8 9 10 11 12 … 46